Press Releases
SOPHiA GENETICS to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
BOSTON and LAUSANNE, Switzerland, Aug. 30, 2021 -- SOPHiA GENETICS SA (Nasdaq: SOPH), today...
SOPHiA GENETICS to Report Second Quarter 2021 Financial Results on September 9, 2021
BOSTON and LAUSANNE, Switzerland, August 26, 2021 — SOPHiA GENETICS SA (Nasdaq: SOPH) today...
Dasa expands partnership with SOPHiA GENETICS for the first decentralized cancer biomarker detection solution in Latin America
Highly accurate HRD detection offers affordable and easily implementable solutions, opening new...
SOPHiA GENETICS Announces Closing of $234 Million Initial Public Offering and $20 Million Private Placement
BOSTON and LAUSANNE, Switzerland, July 27, 2021 -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator...
SOPHiA GENETICS Announces Pricing of Initial Public Offering
BOSTON and LAUSANNE, Switzerland, July 22, 2021 -- SOPHiA GENETICS SA, the creator of a global...
GE Healthcare and SOPHiA GENETICS to collaborate to match treatments to multimodal patient data and cancer type
Chicago/Boston — July 6, 2021: GE Healthcare and SOPHiA GENETICS today...
SOPHiA GENETICS Announces Filing of Registration Statement for Proposed Initial Public Offering
BOSTON and LAUSANNE, Switzerland, July 2, 2021 -- SOPHiA GENETICS SA, the...
SOPHiA DDM™ for TSO500 Furthers Analytical Capabilities
BOSTON and LAUSANNE, Switzerland, July 1, 2021 -- SOPHiA GENETICS,...
SOPHiA GENETICS advances blood cancer genomic testing with new myeloid solutions
Targets DNA variants and RNA fusion genes for blood cancers, including challenging biomarkers...
SOPHiA GENETICS and Hitachi announce collaboration to advance data-driven precision medicine
Multi-year agreement to expand commercial footprint with world-leading genomics platform and...
SOPHiA GENETICS appoints Ross Muken as chief financial officer
Boston, MA, USA, and Lausanne, SWITZERLAND, February 11, 2021 – SOPHiA GENETICS, a global...
SOPHiA GENETICS and the Spanish Lung Cancer Group Team Up to Explore the Predictive Potential of Multimodal Health Data in Resectable Stage IIIA Non-Small Cell Lung Cancer
Lausanne, Switzerland and Boston, MA, USA – February 8, 2021: SOPHiA GENETICS, a global...
